alexa Radical prostatectomy for clinical stage T3a disease.
Haematology

Haematology

Journal of Blood & Lymph

Author(s): Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC

Abstract Share this page

Abstract BACKGROUND: Men with clinical stage T3a disease are at high risk and are often encouraged to undergo radiation therapy with concomitant hormonal therapy. The long-term outcomes among men treated with radical prostatectomy for clinical stage T3a disease were examined. METHODS: Among 3397 men treated by radical prostatectomy by 1 surgeon between 1987 and 2003, 62 (1.8\%) men were identified who had clinical stage T3a disease. Among the 56 men not treated with neoadjuvant or adjuvant therapies before prostate-specific antigen (PSA) recurrence, the long-term outcomes of PSA-free survival, metastasis-free survival, and prostate cancer specific survival were examined. Median and mean follow-up after surgery were 10.3 and 13 years, respectively (range, 1-17). RESULTS: Ninety-one percent of men in this group had pathological T3 disease. PSA-free survival at 15 years after surgery was 49\%. Metastasis-free survival and cause-specific survival at 15 years after surgery were 73\% and 84\%, respectively. Among men with a PSA recurrence, 46\% received secondary therapy before metastasis. The only preoperative or pathological feature that predicted risk of prostate cancer death was lymph node metastasis (hazard ratio [HR]: 9.22, 95\% confidence interval [CI]: 1.06-80.02, P = .044). Among the 28 men with a PSA recurrence, PSA doubling time (PSADT) data were available for 23, of which 11 (48\%) has a PSADT >/=9 months. No patient with a PSADT >/=9 months died of prostate cancer. A PSADT <9 months was significantly associated with increased risk of prostate cancer death (log-rank, P = .004). CONCLUSIONS: In a select cohort of men with clinical stage T3a disease, radical prostatectomy alone provides long-term cancer control in about half of the men and results in a prostate cancer-specific survival of 84\%. Among men with a PSA recurrence, PSADT at the time of recurrence is a useful determinant of risk of prostate cancer death. (c) 2007 American Cancer Society. This article was published in Cancer and referenced in Journal of Blood & Lymph

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords